INSUSENSE THERAPEUTICS
More informations about "Insusense Therapeutics"
Insusense Therapeutics - Crunchbase Company Profile & Funding
Insusense Therapeutics is located in Copenhagen, Hovedstaden, Denmark. Who are Insusense Therapeutics 's competitors? Alternatives and possible competitors to Insusense Therapeutics …See details»
InsuSense 2025 Company Profile: Valuation, Funding & Investors
InsuSense Therapeutics, Diabeticon, Insusense Biopharma, Insusense Biopharmaceuticals, Insusense Pharma, Insusense Pharmaceuticals, Vesper Bio, Vesper Biotechnology …See details»
Insusense - VentureRadar
Insusense Therapeutics is developing novel innovative drugs for the treatment of diabetes based on the world leading research in role of the sortilin protein family conducted by Professor …See details»
Lundbeck Foundation doubles its investment in Aarhus-based …
Oct 20, 2015 Lundbeck Foundation has invested in Insusense Therapeutics due to the outstanding innovation and significant level of inventiveness to be found in the company. If the …See details»
InsuSense Therapeutics - Products, Competitors, Financials, …
InsuSense Therapeutics is a product-focused biotechnology company. Use the CB Insights Platform to explore InsuSense Therapeutics's full profile. InsuSense Therapeutics - Products, …See details»
InsuSense Therapeutics - VentureRadar
Nov 5, 2018 Similar Companies: Asahi Glass Japan Publicly Traded The AGC Group, with Tokyo-based Asahi Glass Co., Ltd. at its core, is a world-leading supplier of flat, automotive …See details»
A researcher with patents and a newly founded company for his …
The purpose of InsuSense is to develop and perfect new medicines to treat diabetes and obesity from a commercial standpoint – and with a licence from Aarhus University. Expectations are …See details»
Insusense Therapeutics ApS Company Profile, Financial and
Insusense Therapeutics ApS is a biopharmaceutical company which develops diabetes type 2 and obesity medicines. The company was incorporated in 2010 and is based in Aarhus, …See details»
Insusense Therapeutics - Drug pipelines, Patents, Clinical trials
Last update 19 Sep 2024. Insusense Therapeutics. Private Company |See details»
Insusense patents new sortilin receptor-targeting compounds
Nov 17, 2022 Insusense ApS has divulged drugs targeting sortilin receptor reported to be useful for the treatment of neurodegeneration, cancer, pain, diabetes, diabetic retinopathy, …See details»
InsuSense Therapeutics Company Profile | Management and
Find contact information for InsuSense Therapeutics. Learn about their Business Services market share, competitors, and InsuSense Therapeutics's email format.See details»
InsuSense Therapeutics Stock Price, Funding, Valuation, Revenue ...
See InsuSense Therapeutics funding rounds, investors, investments, exits and more. Evaluate their financials based on InsuSense Therapeutics's post-money valuation and revenue.See details»
Christian E. Elling - Managing Partner, Lundbeckfonden BioCapital ...
Additionally, Christian E. Elling has had 2 past jobs including CEO at Insusense Therapeutics. Lundbeckfonden Emerge Managing Partner, Lundbeckfonden BioCapital Apr 2012 …See details»
Vesper Bio - Lundbeckfonden
Oct 20, 2015 Vesper Bio is a clinical stage biotech and world leader in sortilin receptor biology developing a rich pipeline of first-in-class small molecule sortilin modulators for a number of …See details»
Insusense describes new sortilin antagonists | BioWorld
Sep 18, 2023 Insusense describes new sortilin antagonists Sep. 18, 2023 Insusense ApS has identified sortilin (NT3; Gp95) antagonists reported to be useful for the treatment of …See details»
InsuSense Therapeutics - Overview, News & Competitors - ZoomInfo
InsuSense Therapeutics - Business Information. Business Services · United States · <25 Employees. InsuSense Therapeutics is a product-focused biotechnology company working on …See details»
Insusense ApS - Drug pipelines, Patents, Clinical trials - Synapse
100 Translational Medicine associated with Insusense ApS. Login to view more data. Corporation Tree. Boost your research with our corporation tree data. login. or. view full example data. …See details»
Insusense patents sortilin antagonists | BioWorld
Mar 27, 2023 A recent Insusense ApS patent describes 2-amino-5,5-dimethylhexanoic acid derivatives as sortilin (NT3; Gp95) antagonists. They are reported to be useful for the …See details»
VES-001 - Drug Targets, Indications, Patents - Synapse - Patsnap
6 days ago Inactive Organization-License Organization-Drug Highest Phase Phase 2. First Approval Date-Regulation-Login to view timeline. Related. 3. Clinical Trials associated with …See details»
New sortilin modulators identified at Insusense - | BioWorld
Insusense has divulged pyridine derivatives targeting sortilin (neurotensin NTR3; NT3; Gp95) receptors reported to be useful for the treatment of neurodegenerative disorders, cancer, pain, …See details»